Global Antifungal Agents Market

Antifungal Agents Market Size, Share, Growth Analysis, By Drug Type(Echinocandins, Azoles, Ployenes, Allylamines), By Therapeutic Indication(Aspergillosis, Dermatophytosis, Candidiasis, and Others), By Application(Powders, Ointments, Drugs, and Pastes), By Region - Industry Forecast 2024-2031


Report ID: SQMIG35J2113 | Region: Global | Published Date: May, 2024
Pages: 219 | Tables: 94 | Figures: 76

Antifungal Agents Market Competitive Landscape

Antifungal agent manufacturers should invest heavily in R&D of novel agents and drugs that can be used for a wide variety of fungal infections. Antifungal agent companies can collaborate and partner with each other to fast track the development and launch of novel products going forward.

Top Player’s Company Profiles

  • Asperqillus
  • Alternaria
  • Sun Pharmaceutical Industries Ltd.
  • Eli Lily Company
  • Pfizer
  • GlaxoSmithKline
  • Sumitomo Dainippon Pharma Co. Ltd.
  • Bayer Healthcare
  • Glenmark
  • Novartis
  • Cosmo Pharmaceuticals NV
  • Sanofi-Aventis
  • Astellas Pharma
  • Teva Pharmaceutical Industries Ltd.
  • Merck & Co.
  • Kramer Laboratories
  • Abbott Laboratories
  • Enzon Pharmaceuticals
  • Gilead
  • Zydus Cadila Healthcare Ltd.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Antifungal Agents Market size was valued at USD 14.4 billion in 2022 and is poised to grow from USD 14.98 billion in 2023 to USD 20.5 billion by 2031, growing at a CAGR of 4% in the forecast period (2024-2031).

Antifungal agent manufacturers should invest heavily in R&D of novel agents and drugs that can be used for a wide variety of fungal infections. Antifungal agent companies can collaborate and partner with each other to fast track the development and launch of novel products going forward. 'Asperqillus', 'Alternaria', 'Sun Pharmaceutical Industries Ltd.', 'Eli Lily Company', 'Pfizer', 'GlaxoSmithKline', 'Sumitomo Dainippon Pharma Co. Ltd.', 'Bayer Healthcare', 'Glenmark', 'Novartis', 'Cosmo Pharmaceuticals NV', 'Sanofi-Aventis', 'Astellas Pharma', 'Teva Pharmaceutical Industries Ltd.', 'Merck & Co.', 'Kramer Laboratories', 'Abbott Laboratories', 'Enzon Pharmaceuticals', 'Gilead', 'Zydus Cadila Healthcare Ltd.'

Widespread antibiotic resistance and growing incidence of infectious chronic diseases are key factors responsible for increasing fungal infections among patients, which in turn, is projected to boost antifungal agent demand outlook.

Personalized Medicine: Antifungal agent vendors can collaborate and partner with personalized medicine companies to develop specialized treatments using antifungal agents for patients affected with different kinds of fungal infections. Antifungal agents companies can take advantage of advancements in different personalized medicine approaches to maximize their revenue generation.

North America is estimated to account for a substantial share of the antifungal agents market owing to rising cases of fungal infections in this region. of a developed healthcare infrastructure and growing investments in the R&D of novel antifungal drugs and medications are also contributing to the dominance of this segment over the coming years. Increasing cases of antifungal resistance in this region will also boost market growth going forward. The United States is forecasted to spearhead the demand for antifungal agents in the long run.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Antifungal Agents Market

Report ID: SQMIG35J2113

$5,300
BUY NOW GET FREE SAMPLE